Cost-Effectiveness of Omalizumab in Chronic Idiopathic Urticaria Refractory to H1-Antihistamines in Turkey

奥马佐单抗 医学 药物经济学 耐火材料(行星科学) 儿科 成本效益 内科学 免疫球蛋白E 重症监护医学 免疫学 抗体 物理 天体生物学 风险分析(工程)
作者
Mehtap Tatar,Şaban Cem Sezen,Ayşegül Şentürk,Maria‐Magdalena Balp,Mete Şaylan,A Keskinaslan
出处
期刊:Value in Health [Elsevier BV]
卷期号:17 (7): A604-A604 被引量:2
标识
DOI:10.1016/j.jval.2014.08.2101
摘要

Omalizumab is a humanised anti-IgE recombinant monoclonal antibody approved in Turkey for treatment of chronic idiopathic (or spontaneous) urticaria (CIU) in patients resistant to standard treatment. We aimed to assess the cost-effectiveness of omalizumab compared with the standard care in the treatment of CIU patients in Turkey. A Markov model of 10 years horizon was developed to estimate costs and outcomes associated with omalizumab 300mg/every 4 weeks and standard of care for 24 weeks (SoC=licensed dose H1 antihistamines) using data from two phase III studies (ASTERIA I&II includes patients with CIU refractory to licensed dose of H1-antihistamines). The study was undertaken from a Turkish health care payer perspective. At the end of this period, omalizumab was stopped and background medication continued. Patients who have responded were retreated by the same strategy upon relapse (UAS7 ≥16 or ≥28). We used Urticaria Activity Score 7 (UAS7) to measure the outcome of the treatment and we used symptom free days (UAS7 ≤6) as the outcome measure in this cost effectiveness analysis. Resource utilization data were obtained via a Delphi panel. Unit costs were taken from the Social Security Institution’s official list. Costs and outcomes were evaluated over a lifetime and discounted at 3%. Results were presented as incremental cost/symptom free days. The incremental symptom free days with omalizumab versus SoC was 27,965 days and the incremental cost was 1,610,349 Turkish Liras for 100 patients over 10 years. The incremental cost per symptom free day was 57.59 Turkish Liras. One-way sensitivity analyses confirmed the robustness of the model results. CIU affects the quality of life of patients and is associated with direct and indirect costs to payers and society. We believe that omalizumab 300mg Q4wks is a cost-effective treatment option for patients with refractory CIU in Turkish setting.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
啵噜噜噜啊完成签到,获得积分10
4秒前
OYY完成签到 ,获得积分10
4秒前
烂漫的断秋完成签到 ,获得积分10
5秒前
6秒前
6秒前
Lucas应助Livrik采纳,获得10
7秒前
cyn0762完成签到,获得积分10
7秒前
点到为止完成签到,获得积分10
8秒前
9秒前
Akim应助lll采纳,获得10
10秒前
高贵灵槐完成签到 ,获得积分10
11秒前
14秒前
wxh完成签到 ,获得积分20
14秒前
量子星尘发布了新的文献求助10
14秒前
liuzi发布了新的文献求助20
15秒前
雨过天晴完成签到,获得积分10
16秒前
花花完成签到 ,获得积分10
17秒前
18秒前
20秒前
汪汪发布了新的文献求助10
23秒前
23秒前
24秒前
27秒前
追寻筮关注了科研通微信公众号
27秒前
miaojuly发布了新的文献求助10
28秒前
充电宝应助汪汪采纳,获得10
29秒前
30秒前
涵哈哈哈哈哈完成签到 ,获得积分10
32秒前
34秒前
liuzi完成签到,获得积分10
34秒前
科目三应助油菜的星星采纳,获得10
36秒前
36秒前
36秒前
37秒前
37秒前
木心应助高院士采纳,获得60
38秒前
38秒前
38秒前
39秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988868
求助须知:如何正确求助?哪些是违规求助? 3531255
关于积分的说明 11253071
捐赠科研通 3269858
什么是DOI,文献DOI怎么找? 1804822
邀请新用户注册赠送积分活动 881994
科研通“疑难数据库(出版商)”最低求助积分说明 809035